SB203580

Protein kinase inhibitor

Cell permeable, specific inhibitor of p38 (SAPK2a). Inhibits p38 MAPK stimulation of MAPKAPK2 (IC₅₀=70nM). Can inhibit the key cell cycle event of retinoblastoma protein phosphorylation in interleukin-2-stimulated T cells. Studies on the proximal regulator of this event, the PI(3)K (phosphoinositide 3-kinase)/Akt (protein kinase B; PKB) pathway, showed that SB203580 blocks the phosphorylation and activation of Akt by inhibiting the Akt kinase, phosphoinositide-dependent protein kinase 1 (PDK1).

The concentrations of SB203580 required to block Akt phosphorylation (IC $_{50}$ = 3-5µM) are only approximately 10-fold higher than those required to inhibit p38 MAP kinase (IC $_{50}$ =0.3-0.5µM). These data define a new activity for this drug and suggest that extreme caution should be used when interpreting data when SB203580 has been used at concentrations above 1-2µM. Non-specific effects include inhibition of COX-1 and -2. Enhances clonal growth of skin epithelial progenitor cells and stimulates neural stem cell proliferation.

Citations: 82

View Online »


Ordering Information

Order Online »

BML-EI286-0001	1mg
BML-EI286-0005	5mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-

pyridyl)1H-imidazole

Appearance White to off-white powder.

CAS 152121-47-6

Couple Target p38, Phosphoinositide-dependent protein kinase

Couple Type Inhibitor

Formula $C_{21}H_{16}N_3FOS$

MW 377.4

Purity ≥97% (HPLC)

Soluble in DMSO (50mg/ml).

Technical Info / Product Notes Replacement for ADI-HPK-110

Last modified: May 29, 2024

